AKT1 and chronic myelogenous leukemia, BCR-ABL1 positive: Furthermore, concurrent treatment with antagomiR-21 and IM markedly increased the efficacy of IM and apoptosis of CD34+ CML cells without affecting normal CD34+ cells by blocking the PI3K/AKT signaling pathway [40].